Halozyme names Darren Snellgrove as CFO, effective June 8, 2026

HALOZYME THERAPEUTICS, INC.

Darren Snellgrove appointed CFO effective June 8, 2026; previously VP IR at Johnson & Johnson and CFO of its Pharmaceuticals sector.
Compensation: $670,000 annual salary, 50% bonus target, $350,000 sign-on cash bonus, and $7.2M new-hire equity awards ($3.2M RSUs + $4M options).
2027 long-term incentive minimum $4M; make-whole RSUs vest over 3 years, stock options vest 25% after 1 year then monthly.
David Ramsay, interim CFO, will assume advisory role effective June 8, 2026 to assist transition.
Snellgrove holds MBA from Villanova, BA from University of Southampton; no family relationships or material interests in transactions.

item 5.02item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

David Ramsay

Advisor

HALO · HALOZYME THERAPEUTICS, INC.

Effective: 2026-06-08
Successor: Darren Snellgrove
Filed: Apr 30, 2026 23:59 UTC

Effective as of June 8, 2026, David Ramsay, the Company’s current Interim CFO, will assume an advisory role with the Company to assist during a brief transition period.

Appointed

Darren Snellgrove

Chief Financial Officer

HALO · HALOZYME THERAPEUTICS, INC.

Effective: 2026-06-08
Filed: Apr 30, 2026 23:59 UTC

Halozyme Therapeutics, Inc. (the “Company”) announced that Darren Snellgrove has been appointed to serve as the Company’s Chief Financial Officer (“CFO”), effective June 8, 2026.

Source: SEC EDGAR

accession 0001159036-26-000053

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.